Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classement en actions #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Prix de l'action
$0.16328419
Capitalisation boursière
$204.14K
Changement (1 jour)
4.35%
Changement (1 an)
102.45%
Pays
GB
Échange Fusion Antibodies plc (FAB)

Catégorie

Healthcare
Bénéfices pour Fusion Antibodies plc (FAB)
Bénéfices en Sep 2025 TTM : $-2.06M
Selon les derniers rapports financiers de Fusion Antibodies plc, les bénéfices actuels de l'entreprise sont de $-2.06M. En 2024, l'entreprise a réalisé un bénéfice de $-2.89M, une augmentation par rapport à celui de 2023 qui était de $-3.53M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Fusion Antibodies plc de 2013 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -992,770.77%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -225,408.48%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -253,916.57%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -103,830.35%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -70,512.80%
NL